表紙
市場調查報告書

全球製酸藥市場:2019∼2023年

Global Antacids Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 756740
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
全球製酸藥市場:2019∼2023年 Global Antacids Market 2019-2023
出版日期: 2018年12月03日內容資訊: 英文 111 Pages
簡介

全球抗酸藥市場因為市場由不需要處方的OTC藥物獨佔,線上銷售日益增加。由於不需要事前廣泛的產品,線上銷售很容易。

本報告提供全球製酸藥市場相關調查,彙整市場趨勢與各市場區隔概要,各地區趨勢,及打入市場的主要企業簡介與競爭趨勢相關資訊。

第1章 摘要整理

第2章 調查範圍

第3章 市場情況

第4章 市場規模

  • 市場定義
  • 市場規模
  • 市場規模與預測

第5章 波特的五力分析

第6章 各類型市場區隔

第7章 客戶趨勢

第8章 客戶趨勢

第9章 各地區趨勢

  • 各地區市場區隔
  • 各地區比較
  • 南北美洲
  • 亞太地區
  • 歐洲·中東·非洲
  • 市場機會

第10章 促進要素與課題

第11章 市場趨勢

第12章 供應商環境

第13章 供應商分析

  • 網羅的供應商
  • 供應商分類
  • 供應商的市場定位
  • Bayer
  • GlaxoSmithKline
  • Johnson & Johnson Services
  • Novartis
  • Sanofi

第14章 附錄

目錄
Product Code: IRTNTR30359

About this market:

The global antacids market sees an increasing trend of online transactions as the market is dominated by OTC drugs that require no prescription. It is easy for the consumption to shop online without requiring prior extensive product knowledge. The major reason for the increased popularity of e- commerce retailing has been the retailer's efforts on improving the online shopping experience through better online education and targeted marketing. This increases the comfort level of consumers buying a product online. Therefore, several organizations have come up to tap this market potential, thereby fueling market growth.

Market Overview:

Increasing use of NSAIDs

NSAIDS have been used for many years for the treatment of arthritis and inflammation and protection from cardiovascular. NSAIDs is expected to increase with the increasing aging population and potential news indications. Therefore, NSAIDs are associated with several gastric problems, including dyspeptic symptoms and the development of gastric ulceration.

Counterfeit drugs

The probability of buying counterfeit drugs in the global antacids market is high as the market is dominated by generics and OTC drugs. The consumption of counterfeit drugs can affect the health of the consumer, and their availability in the market can affect the sales of branded drugs.

For the detailed list of factors that will drive and challenge the growth of the antacids market during the 2019-2023, view our report.

Competitive Landscape:

The antacids market is fragmented owing to the presence of several established and regional vendors. This antacids industry research report focuses on the competitive landscape and lists the various products and services offered by the leading companies. The global antacids market analysis report will also help clients in gauging the market competition and identifying new growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

PART 07: CUSTOMER LANDSCAPE

  • Market segmentation by type
  • Comparison by type
  • Non-systemic antacids - Market size and forecast 2018-2023
  • Systemic antacids - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges
  • PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer
  • GlaxoSmithKline
  • Johnson & Johnson Services
  • Novartis
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global GERD market
  • Exhibit 03: Segments of global GERD market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Non-systemic antacids - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Non-systemic antacids - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Systemic antacids - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Systemic antacids - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Key leading countries
  • Exhibit 34: Market opportunity
  • Exhibit 35: Decision framework
  • Exhibit 36: Global prevalence of geriatric population
  • Exhibit 37: Impact of drivers and challenges
  • Exhibit 38: Drugs that underwent prescription to OTC switch in US
  • Exhibit 39: Vendor landscape
  • Exhibit 40: Landscape disruption
  • Exhibit 41: Vendors covered
  • Exhibit 42: Vendor classification
  • Exhibit 43: Market positioning of vendors
  • Exhibit 44: Bayer - Vendor overview
  • Exhibit 45: Bayer - Business segments
  • Exhibit 46: Bayer - Organizational developments
  • Exhibit 47: Bayer - Geographic focus
  • Exhibit 48: Bayer - Segment focus
  • Exhibit 49: Bayer - Key offerings
  • Exhibit 50: Bayer - Key customers
  • Exhibit 51: GlaxoSmithKline - Vendor overview
  • Exhibit 52: GlaxoSmithKline - Business segments
  • Exhibit 53: GlaxoSmithKline - Organizational developments
  • Exhibit 54: GlaxoSmithKline - Geographic focus
  • Exhibit 55: GlaxoSmithKline - Segment focus
  • Exhibit 56: GlaxoSmithKline - Key offerings
  • Exhibit 57: GlaxoSmithKline - Key customers
  • Exhibit 58: Johnson & Johnson Services - Vendor overview
  • Exhibit 59: Johnson & Johnson Services - Business segments
  • Exhibit 60: Johnson & Johnson Services - Organizational developments
  • Exhibit 61: Johnson & Johnson Services - Geographic focus
  • Exhibit 62: Johnson & Johnson Services - Segment focus
  • Exhibit 63: Johnson & Johnson Services - Key offerings
  • Exhibit 64: Johnson & Johnson Services - Key customers
  • Exhibit 65: Novartis - Vendor overview
  • Exhibit 66: Novartis - Business segments
  • Exhibit 67: Novartis - Organizational developments
  • Exhibit 68: Novartis - Geographic focus
  • Exhibit 69: Novartis - Segment focus
  • Exhibit 70: Novartis - Key offerings
  • Exhibit 71: Novartis - Key customers
  • Exhibit 72: Sanofi - Vendor overview
  • Exhibit 73: Sanofi - Business segments
  • Exhibit 74: Sanofi - Organizational developments
  • Exhibit 75: Sanofi - Geographic focus
  • Exhibit 76: Sanofi - Segment focus
  • Exhibit 77: Sanofi - Key offerings
  • Exhibit 78: Sanofi - Key customers
  • Exhibit 79: Validation techniques employed for market sizing
  • Exhibit 80: List of abbreviations